CASE-BASED ROUNDTABLE

NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

Latest Articles

Factors Affecting First-Line ICI Choice in HER2-Negative Gastric Cancer

Factors Affecting First-Line ICI Choice in HER2-Negative Gastric Cancer

During a live event, Zev Wainberg, MD, and participants discussed frontline immunotherapy selection in advanced HER2-negative gastrointestinal cancers.

Experts Weigh Fixed-Duration Approaches in Frontline CLL

Experts Weigh Fixed-Duration Approaches in Frontline CLL

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

Navigating Treatment Selection for Advanced NETs

Navigating Treatment Selection for Advanced NETs

Explore how GI and pancreatic NET sites shape symptoms and survival, plus NCCN-backed therapies from somatostatin analogs to PRRT and cabozantinib.

Considerations With Luspatercept Failure in Lower-Risk MDS

Considerations With Luspatercept Failure in Lower-Risk MDS

During a live event, Andrew Brunner, MD, and participants discussed escalating therapy in luspatercept-refractory LR-MDS.

Availability, Tolerability, and Drug Interactions Drive ARPI Selection in mHSPC

Availability, Tolerability, and Drug Interactions Drive ARPI Selection in mHSPC

During a live event, Matthew Rettig, MD, and participating oncologists discussed a case of a 74-year-old man with metastatic hormone-sensitive prostate cancer.

Oncologists Weigh Tivozanib Data in Pretreated Metastatic RCC

Oncologists Weigh Tivozanib Data in Pretreated Metastatic RCC

Experts debate tivozanib’s durable responses and tolerability after immunotherapy in metastatic RCC, shaping smarter VEGFR-TKI sequencing.

Defining Key Questions on Adopting Quadruplet Regimens in NDMM

Defining Key Questions on Adopting Quadruplet Regimens in NDMM

During a live event, Gurbakhash Kaur, MD, and Donna Catamero, ANP-BC, OCN, CCRC, and participants discussed frontline treatment selection, duration of therapy, and the emerging role of MRD-guided decision-making in newly diagnosed multiple myeloma.

Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera

Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera

During a live event, Kristen M. Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course.

Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC

Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC

During a live event, Julia Rotow, MD, and participants discussed how community oncologists are managing chemotherapy-induced neutropenia in extensive-stage small cell lung cancer.

Safety, Functionality, and Overall QOL Considerations in Third-Line KRAS-Mutant CRC

Safety, Functionality, and Overall QOL Considerations in Third-Line KRAS-Mutant CRC

During a live event, Christopher Lieu, MD, and participants discussed selecting third-line therapy for KRAS-mutant metastatic colorectal cancer.

When Consensus Outpaces Capacity in Second-Line Melanoma

When Consensus Outpaces Capacity in Second-Line Melanoma

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option

Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

Oncologists Perceive Shift Away from Surgery in Progressive Desmoid Tumors

Oncologists Perceive Shift Away from Surgery in Progressive Desmoid Tumors

During a live event, Brittany Siontis, MD, discussed treatment strategies for a patient with a progressive abdominal desmoid tumor.

The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports

The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma

Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell therapy.

View a specific disease type